July 7, 2021 -- Graphics processing unit (GPU) technology developer Nvidia has launched an artificial intelligence (AI)-powered supercomputer in the U.K. that enables researchers in digital biology and genomics.
Called Cambridge-1, the supercomputer is designed to bolster research in the life sciences industry and represents a $100 million investment by Nvidia. The computer is part of an Nvidia DGX SuperPOD cluster, and it also supports the company's Clara framework and AI to enable large-scale research.
The first research projects with Cambridge-1 are being conducted by AstraZeneca, GSK, Guy's and St. Thomas' National Health Service (NHS) Foundation Trust, King's College London, and Oxford Nanopore Technologies. They include research into developing a better understanding of brain diseases, using AI to develop new drugs, and improving the accuracy of locating disease-causing variations in human genomes.
Over the next 10 years, the Cambridge-1 supercomputer has the potential to create an estimated value of 600 million pounds (about $828 million), according to an estimate by economics consulting firm Frontier Economics.
Cambridge-1 is being used on the following projects: